BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15958060)

  • 1. Cytotoxic effects of pemetrexed in gastric cancer cells.
    Kim JH; Lee KW; Jung Y; Kim TY; Ham HS; Jong HS; Jung KH; Im SA; Kim TY; Kim NK; Bang YJ
    Cancer Sci; 2005 Jun; 96(6):365-71. PubMed ID: 15958060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer.
    Ozasa H; Oguri T; Uemura T; Miyazaki M; Maeno K; Sato S; Ueda R
    Cancer Sci; 2010 Jan; 101(1):161-6. PubMed ID: 19811498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.
    Sigmond J; Backus HH; Wouters D; Temmink OH; Jansen G; Peters GJ
    Biochem Pharmacol; 2003 Aug; 66(3):431-8. PubMed ID: 12907242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.
    Mairinger F; Vollbrecht C; Halbwedl I; Hatz M; Stacher E; Gülly C; Quehenberger F; Stephan-Falkenau S; Kollmeier J; Roth A; Mairinger T; Popper H
    J Thorac Oncol; 2013 May; 8(5):644-53. PubMed ID: 23449276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line.
    Wang Y; Zhao R; Goldman ID
    Biochem Pharmacol; 2003 Apr; 65(7):1163-70. PubMed ID: 12663051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
    Nagai S; Takenaka K; Sonobe M; Wada H; Tanaka F
    Chemotherapy; 2008; 54(3):166-75. PubMed ID: 18560222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
    Zhang D; Ochi N; Takigawa N; Tanimoto Y; Chen Y; Ichihara E; Hotta K; Tabata M; Tanimoto M; Kiura K
    Cancer Lett; 2011 Oct; 309(2):228-35. PubMed ID: 21742432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.
    Christoph DC; Asuncion BR; Mascaux C; Tran C; Lu X; Wynes MW; Gauler TC; Wohlschlaeger J; Theegarten D; Neumann V; Hepp R; Welter S; Stamatis G; Tannapfel A; Schuler M; Eberhardt WE; Hirsch FR
    J Thorac Oncol; 2012 Sep; 7(9):1440-8. PubMed ID: 22895141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
    Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
    Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.
    Wu MF; Hsiao YM; Huang CF; Huang YH; Yang WJ; Chan HW; Chang JT; Ko JL
    J Thorac Oncol; 2010 Aug; 5(8):1143-51. PubMed ID: 20559153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.
    Lustgarten DE; Deshpande C; Aggarwal C; Wang LC; Saloura V; Vachani A; Wang LP; Litzky L; Feldman M; Creaney J; Nowak AK; Langer C; Inghilleri S; Stella G; Albelda SM
    J Thorac Oncol; 2013 Apr; 8(4):469-77. PubMed ID: 23486267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression.
    Hanauske AR; Eismann U; Oberschmidt O; Pospisil H; Hoffmann S; Hanauske-Abel H; Ma D; Chen V; Paoletti P; Niyikiza C
    Invest New Drugs; 2007 Oct; 25(5):417-23. PubMed ID: 17534577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.
    Takezawa K; Okamoto I; Okamoto W; Takeda M; Sakai K; Tsukioka S; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K
    Br J Cancer; 2011 May; 104(10):1594-601. PubMed ID: 21487406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.
    Nagai H; Yasuda H; Hatachi Y; Xue D; Sasaki T; Yamaya M; Sakamori Y; Togashi Y; Masago K; Ito I; Kim YH; Mio T; Mishima M
    Int J Oncol; 2012 Jul; 41(1):24-30. PubMed ID: 22552400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
    Kitazono-Saitoh M; Takiguchi Y; Kitazono S; Ashinuma H; Kitamura A; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Tagawa M; Tatsumi K
    Oncol Rep; 2012 Jul; 28(1):33-40. PubMed ID: 22562354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
    van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
    Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cells.
    Buqué A; Aresti U; Calvo B; Sh Muhialdin J; Muñoz A; Carrera S; Azkona E; Rubio I; López-Vivanco G
    PLoS One; 2013; 8(5):e63338. PubMed ID: 23675481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
    Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
    Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer.
    Wilson PM; LaBonte MJ; Lenz HJ; Mack PC; Ladner RD
    Mol Cancer Ther; 2012 Mar; 11(3):616-28. PubMed ID: 22172489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
    Tung CL; Chiu HC; Jian YJ; Jian YT; Chen CY; Syu JJ; Wo TY; Huang YJ; Tseng SC; Lin YW
    Exp Cell Res; 2014 Apr; 322(2):345-54. PubMed ID: 24530475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.